Medtronic (MDT) said Thursday that it has submitted 510(k) applications to the US Food and Drug Administration (FDA) seeking marketing approval for its MiniMed 780G interoperable pump as an alternate controller enabled insulin pump and SmartGuard algorithm as an interoperable automated glycemic controller.
Medtronic said the submissions are part of a deal announced in August with Abbott Laboratories (ABT) to collaborate on an integrated system based on Abbott's continuous glucose monitoring platform.
Under the agreement, Abbott is supplying Medtronic with a CGM that will work exclusively with Medtronic's smart dosing devices and software.
According to the FDA, a 510(k) is a premarket submission made to FDA to demonstrate that the device to be marketed is as safe and effective as a legally marketed device.
Price: 83.56, Change: -0.19, Percent Change: -0.23
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。